Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 2/20 | 0.32 |
| ▸ | LDHB | P07195 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800801 | 0.90 | CYP3A4 (0.58) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL26469 | 0.90 | CYP3A4 (0.56) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL16168661 | 0.88 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL16168660 | 0.87 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL15800803 | 0.87 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL9813322 | 0.87 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL21699893 | 0.85 | CYP3A4 (0.63) | CYP3A4TSHRCYP1A2TRPA1GABRA1 | |
| SCHEMBL2858280 | 0.84 | CYP3A4 (0.68) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL10919766 | 0.83 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 | |
| SCHEMBL11313261 | 0.83 | CYP3A4 (0.61) | CYP3A4TSHRCYP1A2TRPA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0950080-A2 | COATING COMPOSITION | Bollig & Kemper GmbH & Co. KG (DE) | 1999-10-20 | — | — | EP | claimed |
| WO-1998029195-A2 | COATING COMPOSITION | BOLLIG & KEMPER GMBH & CO. KG (DE) | 1998-07-09 | — | — | WO | claimed |
| US-20240154170-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-3584872-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND POWER STORAGE DEVICE | MITSUBISHI CHEM CORP (JP) | 2023-10-25 | — | — | EP | disclosed |
| EP-4219400-A2 | METHOD FOR PRODUCING LITHIUM FLUOROSULFONATE, LITHIUM FLUOROSULFONATE, USE OF LITHIUM FLUOROSULFONATE IN A NONAQUEOUS ELECTROLYTIC SOLUTION, AND NONAQUEOUS ELECTROLYTIC SOLUTION | Mitsubishi Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11631895-B2 | Nonaqueous electrolyte solution and energy device using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-04-18 | — | — | US | disclosed |
| EP-3782958-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20220320570-A1 | METHOD FOR PRODUCING LITHIUM FLUOROSULFONATE, LITHIUM FLUOROSULFONATE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-10-06 | — | — | US | disclosed |
| US-11387484-B2 | Method for producing lithium fluorosulfonate, lithium fluorosulfonate, nonaqueous electrolytic solution, and nonaqueous electrolytic solution secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-07-12 | — | — | US | disclosed |
| US-11302966-B2 | Amine borate compound containing nonaqueous electrolytic solution and power storage device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-04-12 | — | — | US | disclosed |
| EP-3782958-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-2958181-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
| EP-2535976-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION, AND SECONDARY BATTERY COMPRISING THE SAME | MITSUBISHI CHEM CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| EP-2863469-A1 | NONAQUEOUS ELECTROLYTE SECONDARY CELL AND METHOD FOR USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8673489-B2 | Nonaqueous electrolytic solution and nonaqeuous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2698350-A1 | METHOD FOR PRODUCING LITHIUM FLUOROSULFONATE, LITHIUM FLUOROSULFONATE, NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-20140038062-A1 | METHOD FOR PRODUCING LITHIUM FLUOROSULFONATE, LITHIUM FLUOROSULFONATE, NONAQUEOUS ELECTROLYTIC SOLUTION, AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20130280622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2535976-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120308881-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQEUOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11631895-B2 | Nonaqueous electrolyte solution and energy device using same | SLC26A3, VDAC3, SLC25A13 | CYP3A4 4041/4885TSHR 3561/4885CYP1A2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.